Ahmet Aydin

Dr. Ahmet Aydin

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 October 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
AKAli Kirik
Ali Kirik
Hilmi Erdem SumbulHilmi Erdem Sumbul
Hilmi Erdem Sumbul
Nizameddin KocaNizameddin Koca
Nizameddin Koca
TKTurkan Pasali Kilit
Turkan Pasali Kilit
SSsibel demiral sezer
sibel demiral sezer
TDTeoman Doğru
Teoman Doğru
Introduction: Metabolic dysfunction-associated steatotic liver disease (MASLD) prevalence data in Türkiye is limited. We aimed to determine the nationwide prevalence of MASLD and advanced hepatic fibrosis risk in subjects with cardiometabolic risk factors (CMRF). Despite recent international consensus redefining fatty liver disease terminology, no nationwide MASLD study has been reported in Türkiye. Methods: This cross-sectional study included 14,371 adults with ≥1 CMRF from 44 centers across 31 cities. MASLD was diagnosed using liver ultrasonography plus cardiometabolic criteria. Advanced fibrosis risk was assessed by fibrosis-4 (FIB-4) score (≥1.3 for ≤65 years; ≥2.0 for >65 years). Logistic regression was used to identify independent predictors of high FIB-4. Results: A total of 61.4% of participants were women, the mean age was 51.3 ± 14.4 years, and the mean BMI was 31.4 ± 6.0 kg/m2. MASLD prevalence was 75.7% (n = 10,873), rising with the number of CMRFs (56.5% with one factor vs. 83.4% with all). The prevalence of high FIB-4 scores was 12.0% overall, being lower in MASLD patients than non-MASLD patients (11.2% vs. 14.4%, p < 0.001). FIB-4 scores decreased with increasing BMI (28.1% underweight vs. 8.7% class III obesity). Male sex, T2DM, and hypertension independently predicted high FIB-4 scores, while smoking, higher BMI, and MASLD were inversely associated. Conclusions: Three-quarters of Turkish adults with CMRF have MASLD. Standard FIB-4 thresholds may underestimate fibrosis risk in obese and smoking populations, underscoring the need for adjusted cut-offs or alternative tools. This study is the first to provide nationwide MASLD prevalence data in Türkiye.

14 April 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
AOAlihan Oral
Alihan Oral
İSİhsan Solmaz
İhsan Solmaz
Nizameddin KocaNizameddin Koca
Nizameddin Koca
UTUlas Serkan Topaloglu
Ulas Serkan Topaloglu
IDIsmail Demir
Ismail Demir
SUSeyit Uyar
Seyit Uyar
Objectives: Obesity is a significant public health concern, as it is associated with the development of numerous chronic diseases. The prevalence of obesity and attendant diseases has been increasing over recent years. This study attempted to ascertain the frequency of chronic diseases in obese patients in Türkiye for the first time on this scale. Methods: A retrospective study was conducted, with patients admitted to the internal medicine outpatient clinics or obesity centers between December 2023 and December 2024 included in this study. Participants were recruited from seven regions, 20 provinces, and 28 centers, and the inclusion criteria were met by those aged 18 years and over with a body mass index (BMI) of 30 kg per square meter (kg/m2) or above. Their status, with respect to chronic diseases, and their anthropometric parameters were documented. Results: The total number of patients was 10,121, with a mean age of 45.2 ± 13.92. Of these, 7222 (71.35%) were female. The prevalence of type 2 diabetes mellitus (T2DM), hypertension (HT), dyslipidemia (DL), coronary artery disease (CAD), obstructive pulmonary disease (OPD), obstructive sleep apnea syndrome (OSAS), and fatty liver disease (FLD) was found to be 35.01%, 78.19%, 12.37%, 10.32%, 5.88%, and 75.12%, respectively. A subsequent analysis of the prevalence of these diseases by region revealed a statistically significant variation between regions (p < 0.001 for all regions). Conclusions: This study represents a substantial contribution to the existing body of knowledge in this field, particularly with regard to the identification of the current chronic disease rate of obese patients in Türkiye.

12 February 2026 in Diagnostics
Verified
Journal Article
Open access
PDF file
Özge Kama BaşcıÖzge Kama Başcı
Özge Kama Başcı
AOAlihan Oral
Alihan Oral
AKAli Kirik
Ali Kirik
HŞHacer Şen
Hacer Şen
İSİhsan Solmaz
İhsan Solmaz
HSHasan Sozel
Hasan Sozel
Background/Objectives: Non-invasive fibrosis scores are widely used for risk stratification in metabolic dysfunction-associated steatotic liver disease (MASLD); however, their performance in obese individuals remains controversial. The Fibrosis-4 (FIB-4) index is commonly recommended as a first-line tool, yet it may underestimate fibrosis risk in severe obesity. The BAST score, which incorporates metabolic and anthropometric parameters, has been proposed as an alternative. This study aimed to characterize both the degree and direction of discordance between FIB-4 and BAST in obese patients with MASLD. Methods: This predefined secondary analysis included 2950 adults with obesity (BMI ≥ 30 kg/m2) and MASLD from the multicenter OBREDI-TR cohort. Fibrosis risk categories were assigned using standard cut-offs for FIB-4 and BAST, and agreement was assessed using weighted Cohen’s kappa. Associations among discordance patterns, obesity class, and the visceral adiposity index (VAI) were evaluated using chi-square tests and general linear models. Results: Overall agreement between FIB-4 and BAST was very poor (κ = 0.041, p < 0.001). Discordance was observed in 22.3% of patients and increased markedly with obesity severity. In class III obesity, discordance was predominantly driven by low-risk classification according to FIB-4 despite high-risk classification according to BAST. Patients with this discordant pattern exhibited significantly higher VAI values than concordant cases (p < 0.001), independently of the study center. Conclusions: In obese patients with MASLD, particularly those with morbid obesity, FIB-4 frequently classifies patients as low risk, while BAST identifies elevated fibrosis risk. This systematic discordance suggests that FIB-4 may underestimate fibrosis burden in the context of severe obesity and visceral adiposity, supporting the need for a phenotype-oriented, multimodal approach to fibrosis risk assessment.

12 November 2025 in Supportive Care in Cancer
Verified
Journal Article
Closed access
PDF file
SASabin Goktas Aydin
Sabin Goktas Aydin
AAAhmet Aydin
Ahmet Aydin
BDBURÇİN ÇAKAN DEMİREL
BURÇİN ÇAKAN DEMİREL
ODOzden Demir
Ozden Demir
ABAyberk Bayramgil
Ayberk Bayramgil
ÇKÇağlar Köseoğlu
Çağlar Köseoğlu

15 April 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
AAAhmet Aydin
Ahmet Aydin
TKTurkan Pasali Kilit
Turkan Pasali Kilit
SKSeher KIR
Seher KIR
EAEşref Araç
Eşref Araç
OÖOsman Özüdoğru
Osman Özüdoğru
Nizameddin KocaNizameddin Koca
Nizameddin Koca
Background: Osteoporosis has a rising global incidence and social burden. Serum uric acid’s dual roles in oxidative stress and inflammation may influence bone health, but findings are inconsistent and require further research. This study aimed to evaluate the relationship between SUA levels and osteoporosis in a multicenter cohort obtained from different regions of Türkiye. Methods: This multi-center retrospective study included 3280 individuals, postmenopausal women and men aged 45 and older, from 16 centers in Türkiye. Individuals were excluded if they recently consumed alcohol, had severe renal dysfunction, certain hormonal or mineral disorders, specific medications, or certain menopausal statuses. Bone mineral density (BMD) at the hip and lumbar spine was measured using dual-energy X-ray absorptiometry (DXA), and participants were classified as normal or having osteopenia or osteoporosis based on T-score thresholds. Results: Overall, 34.8% were male, and 65.2% were female. For the lumbar spine, 36.8% had osteopenia, and 13.5% had osteoporosis; similarly, for the total hip, 40.8% had osteopenia, and 7.9% had osteoporosis. ROC analysis identified a threshold of 3.9 mg/dL serum uric acid (SUA) (AUC 0.374; p < 0.001), which was positively associated with both lumbar and total hip BMD. Osteoporosis rates were higher in patients with SUA < 3.9 mg/dL compared to those with SUA ≥ 3.9 mg/dL at the lumbar spine (29.1% vs. 14.2%, p < 0.001) and total hip sites (23.6% vs. 15.9%, p = 0.003). After adjustment for potential confounders, SUA was a significant independent predictor of osteoporosis in the lumbar spine (OR 0.70; p < 0.001) and the hip (OR 0.80; p < 0.001). Conclusions: Serum uric acid levels are inversely linked to bone mineral density and osteoporosis risk, indicating a potential role in bone health. However, due to study limitations, causal relationships remain unproven, and further research is needed.

30 September 2025 in BMC Cancer
Verified
Journal Article
Open access
SASabin Goktas Aydin
Sabin Goktas Aydin
BOBahar Ozguzel
Bahar Ozguzel
BBBahar Bayramova
Bahar Bayramova
EBErsin Budak
Ersin Budak
EAErkan Aydin
Erkan Aydin
FAFatma Bengu Aydin
Fatma Bengu Aydin
Cognitive impairment is a recognized challenge for cancer survivors, often linked to chemotherapy’s neurotoxic effects. In colorectal cancer (CRC), this impact remains less understood despite emerging evidence. This study aims to evaluate cognitive flexibility, memory, and attention in colorectal cancer patients compared to healthy controls. This prospective study assessed cognitive function in 58 colorectal cancer patients and 32 healthy, age- and education-matched controls. Cognitive testing was conducted within four weeks of chemotherapy completion. Exclusion criteria included pre-existing cognitive issues, brain metastases, and medications affecting cognition. Tests included Sensory Perception, Total Learning Score, Long-Term Memory Score, Stroop Test, and Trail Making Test. The median age of the cancer group was 56.5 years (range: 29–70), while the median age for the control group was 52 years (range: 28–66). Cancer patients demonstrated significantly poorer performance across several cognitive domains. Total Learning Scores were notably lower in the cancer group (mean rank 40.23 vs. 55.05, p = 0.01), indicating reduced learning capacity. Trail Making Test A and B times were significantly longer for cancer patients (p = 0.004), reflecting deficits in visual attention and cognitive flexibility. Stroop Test performance also showed significant delays across all time points (p = 0.002 to p = 0.02), suggesting impaired processing speed and executive control. Subgroup analysis of stage IV patients revealed even greater deficits, with significantly lower Total Learning Scores (p = 0.001) and slower Trail Making Test completion times (p < 0.001). No significant differences emerged in sensory perception or long-term memory. The research revealed significant cognitive difficulties in colorectal cancer patients after undergoing chemotherapy, especially in areas such as learning, attention, and executive function, with the most severe impairments observed in those with stage IV cancer.